Copper(II)-bis(thiosemicarbazonato) complexes as anti-chlamydial agents

Marsh, JW; Djoko, AY; McEwan, AG; Huston, WM

doi:10.1093/femspd/ftx084

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Copper(II)-bis(thiosemicarbazonato) complexes as anti-chlamydial agents

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Marsh, J., Djoko, A., McEwan, A., & Huston, W. (2017). Copper(II)-bis(thiosemicarbazonato) complexes as anti-chlamydial agents. Pathogens and Disease, 75(7): ftx084. doi:10.1093/femspd/ftx084.

Cite as: https://hdl.handle.net/21.11116/0000-000C-BBA9-3

Abstract

Lipophilic copper (Cu)-containing complexes have shown promising antibacterial activity against a range of bacterial pathogens. To examine the susceptibility of the intracellular human pathogen Chlamydia trachomatis to copper complexes containing bis(thiosemicarbazone) ligands [Cu(btsc)], we tested the in vitro effect of CuII-diacetyl- and CuII-glyoxal-bis[N(4)-methylthiosemicarbazonato] (Cu(atsm) and Cu(gtsm), respectively) on C. trachomatis. Cu(atsm) and to a greater extent, Cu(gtsm), prevented the formation of infectious chlamydial progeny. Impacts on host cell viability and respiration were also observed in addition to the Chlamydia impacts. This work suggests that copper-based complexes may represent a new lead approach for future development of new therapeutics against chlamydial infections, although host cell impacts need to be fully explored.